Sign In  |  Register  |  About Walnut Creek Guide  |  Contact Us

Walnut Creek, CA
September 01, 2020 1:43pm
7-Day Forecast | Traffic

  • Search Hotels in Walnut Creek Guide

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Moderna, Inc.

< Previous 1 2 3 4 5 Next >
Moderna Announces New Supply Contract With The U.S. Government For An Initial 66 Million Doses Of A Moderna Bivalent Covid-19 Booster Vaccine With Options For U.S. Government To Purchase Up To An Additional 234 Million Doses
From Moderna, Inc.
Via AccessWire
Exposures COVID-19 Product Safety
Tickers MRNA
EMA Committee for Medicinal Products for Human Use (CHMP) Recommends Use of the Moderna COVID-19 Booster in Adolescents (12-17 Years) in the European Union
From Moderna, Inc.
Via AccessWire
Exposures COVID-19
Tickers MRNA
Therapeutic Goods Administration Grants Provisional Approval for Moderna’s COVID-19 Vaccine in Children Aged Six Months to Five Years
From Moderna, Inc.
Via AccessWire
Exposures COVID-19
Tickers MRNA
Health Canada Authorizes Moderna's COVID-19 Vaccine in Young Children (6 Months-5 Years)
From Moderna, Inc.
Via AccessWire
Exposures COVID-19
Tickers MRNA
Moderna to Report First Quarter Financial Results on Wednesday, August 3, 2022
From Moderna, Inc.
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Tickers MRNA
Moderna Announces First Participant Dosed in a Phase 1 Trial of its Nipah Virus mRNA Vaccine, mRNA-1215
From Moderna, Inc.
Via AccessWire
Tickers MRNA
Moderna's Omicron-Containing Bivalent Booster Candidate, mRNA-1273.214, Demonstrates Significantly Higher Neutralizing Antibody Response Against Omicron Subvariants BA.4/5 Compared To Currently Authorized Booster
From Moderna, Inc.
Via AccessWire
Exposures Product Safety
Tickers MRNA
Moderna Announces Bivalent Booster mRNA-1273.214 Demonstrates Potent Neutralizing Antibody Response Against Omicron Subvariants BA.4 And BA.5
From Moderna, Inc.
Via AccessWire
Exposures COVID-19
Tickers MRNA
Moderna Announces Plan to Bring mRNA Innovation to the United Kingdom
From Moderna, Inc.
Via AccessWire
Tickers MRNA
Moderna Receives FDA Authorization for Emergency Use of Its COVID-19 Vaccine for Children 6 Months of Age and Older
From Moderna, Inc.
Via AccessWire
Exposures COVID-19 Product Safety
Tickers MRNA
Moderna Announces Omicron-Containing Bivalent Booster Candidate mRNA-1273.214 Demonstrates Superior Antibody Response Against Omicron
From Moderna, Inc.
Via AccessWire
Tickers MRNA
Moderna Announces First Participants Dosed in Phase 3 Study of Seasonal Influenza Vaccine Candidate (mRNA-1010)
From Moderna, Inc.
Via AccessWire
Exposures COVID-19
Tickers MRNA
Moderna and the European Commission Agree on Amendment to COVID-19 Vaccine Supply Agreement
From Moderna, Inc.
Via AccessWire
Exposures COVID-19
Tickers MRNA
Moderna to Present at Upcoming Conferences in June 2022
From Moderna, Inc.
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Tickers MRNA
Moderna and Takeda Announce Plans to Transfer Marketing Authorization for Spikevax(TM) COVID-19 Vaccine in Japan to Moderna
From Moderna, Inc.
Via AccessWire
Exposures COVID-19
Tickers MRNA TAK
Moderna to Present at the UBS 2022 Global Healthcare Conference
From Moderna, Inc.
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Tickers MRNA
IAVI and Moderna Launch First-in-Africa Clinical Trial of mRNA HIV Vaccine Development Program
From Moderna, Inc.
Via AccessWire
Tickers MRNA
Moderna Announces Advancements in mRNA Platform Science for Application Across Multiple Diseases at Science and Technology Day
From Moderna, Inc.
Via AccessWire
Tickers MRNA
Moderna to Host Annual Science and Technology Day on May 17, 2022
From Moderna, Inc.
Via AccessWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Tickers MRNA
Moderna Reports First Quarter 2022 Financial Results and Provides Business Updates
From Moderna, Inc.
Via AccessWire
Exposures COVID-19
Tickers MRNA
Moderna Files to Expand Conditional Marketing Authorization for Its COVID-19 Vaccine to Include Children Six Months to Under Six Years in The European Union
From Moderna, Inc.
Via AccessWire
Exposures COVID-19
Tickers MRNA
Moderna Finalizes Plan for Long-Term Strategic Partnership with The Government of Canada
From Moderna, Inc.
Via AccessWire
Tickers MRNA
Moderna Files for Authorization of Its COVID-19 Vaccine in Young Children Six Months to Under Six Years of Age
From Moderna, Inc.
Via AccessWire
Exposures COVID-19
Tickers MRNA
Arpa Garay Joins Moderna as Chief Commercial Officer
From Moderna, Inc.
Via AccessWire
Tickers MRNA
Moderna Announces Clinical Update on Bivalent COVID-19 Booster Platform
From Moderna, Inc.
Via AccessWire
Exposures COVID-19
Tickers MRNA
Moderna to Report First Quarter Financial Results on Wednesday, May 4, 2022
From Moderna, Inc.
Via AccessWire
Tickers MRNA
Jorge Gomez Joins Moderna as Chief Financial Officer
From Moderna, Inc.
Via AccessWire
Tickers MRNA
Moderna Announces First Participants Dosed in Phase 1/2 Study with mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccine Candidates
From Moderna, Inc.
Via AccessWire
Tickers MRNA
IAVI and Moderna Partner to Tackle Broad Global Health Priorities Using mRNA for Vaccines and Antibodies
From Moderna, Inc.
Via AccessWire
Topics Death
Exposures COVID-19 Death
Tickers MRNA
Moderna Launches New Charitable Foundation
From Moderna, Inc.
Via AccessWire
Exposures COVID-19
Tickers MRNA
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 WalnutCreekGuide.com & California Media Partners, LLC. All rights reserved.